Clovis Oncology

Clovis Oncology, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of innovative anti-cancer agents in the United States, Europe, and additional international markets. Its U.S. marketed product, Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP), is approved for use in the maintenance treatment and treatment of eligible adult patients with recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer, and also for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC), which have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. In Europe, Rubraca is approved for use in recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. The company was founded by Andrew R. Allen, Gillian C. Ivers-Read, Patrick J. Mahaffy, and Erle T. Mast on April 20, 2009 and is headquartered in Boulder, CO.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Clovis Oncology is a biopharmaceutical company focused on acquiring, developing and commercializing cancer treatments in the United States, Europe and other international markets. Their development programs are targeted at specific subsets of cancer, combining precision medicine with companion diagnostics to direct therapeutics to those patients most likely to benefit from them.

The company might have vanquished delisting concerns with its surge.

Why Clovis Oncology Shares Jumped 158.9% in June

A key label expansion for the company's ovarian cancer drug could take longer than expected.

Why Clovis Oncology Stock Is Taking a Step Backward Today

Clovis (CLVS) stock is on investors' radars as its shareholder meeting is resuming today. The company is seeking approval for a reverse split.

Why Is Clovis Oncology (CLVS) Stock in the Spotlight Today?

AMC Entertainment

CuriosityStream

Douglas Elliman

Gevo

Gran Tierra Energy

National CineMedia

Consider these seven names, a mix of growth and value plays, some of the best penny stocks to buy in July 2022. The post 7 Penny Stocks to Buy in July 2022 appeared first on InvestorPlace.

7 Penny Stocks to Buy in July 2022

Clovis Oncology (CLVS) stock is heading higher on Friday and investors will want to watch the company's shares when July 7 rolls around! The post Dear CLVS Stock Fans, Mark Your Calendars for July 7 appeared first on InvestorPlace.

Dear CLVS Stock Fans, Mark Your Calendars for July 7

Benitec Biopharma Limited Sponsored ADR

Invitae

Alaunos Therapeutics

Biotech penny stocks to watch right now. The post Penny Stocks To Buy Now?

Penny Stocks To Buy Now? 4 Biotech Stocks To Watch Before July 2022

Today, investors in Clovis Oncology are cheering about more positive clinical trial results as CLVS stock soars 50%. The post CLVS Stock Alert: 7 Things to Know as Clovis Oncology Soars 70% appeared first on InvestorPlace.

CLVS Stock Alert: 7 Things to Know as Clovis Oncology Soars 70%

BlackSky Technology

Mullen Automotive

Check these 3 penny stocks out for your watchlist right now The post Best Penny Stocks to Buy This Week? 3 to Watch as June Ends  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Best Penny Stocks to Buy This Week? 3 to Watch as June Ends

It reported some great initial data from one of its phase 1 clinical trials.

Why Clovis Oncology Stock Is Blasting Off Today

Endo International

VBI Vaccines

Check these three biotech penny stocks out for your watchlist right now The post 3 Biotech Penny Stocks That Climbed in After-Hours Trading appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Biotech Penny Stocks That Climbed in After-Hours Trading

Today has been another strong one for investors in Clovis Oncology and CLVS stock, with this company surging another 20% in today's session. The post Clovis Oncology (CLVS) Stock Gains 20% on Tumor Trials, Buyout Hopes appeared first on InvestorPlace.

Clovis Oncology (CLVS) Stock Gains 20% on Tumor Trials, Buyout Hopes

Clovis Oncology (CLVS) reports favorable data from a study, which supports the potential clinical utility of FAP-2286, its targeted radiotherapy candidate, as a treatment for advanced solid tumors.

Clovis (CLVS) Up 19.4% on Upbeat Data From Solid Tumor Study

Applied UV

Hut 8 Mining Corp

OptiNose

Penny Stocks To Watch Right Now The post Best Penny Stocks To Buy Now? 4 To Watch After June's Fed Meeting appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Best Penny Stocks To Buy Now? 4 To Watch After June's Fed Meeting

Clovis Oncology Inc (NASDAQ: CLVS) announced a presentation detailing initial Phase 1 data from Phase 1/2 LuMIERE clinical study of FAP-2286 labeled with lutetium-177 (177Lu-FAP-2286).  Overall, in nine patients treated in the first two dose cohorts, 177Lu-FAP-2286 demonstrated.

Clovis Shares Jumps After Highlighting Data From Targeted Radiotherapy Trial

BOULDER, Colo.--(BUSINESS WIRE)---- $CLVS--Clovis Oncology Highlights Phase 1 Data from Ongoing Clinical Studies of Targeted Radiotherapy Candidate FAP-2286 at SNMMI Annual Meeting

Clovis Oncology Highlights Phase 1 Data from Ongoing Clinical Studies of Targeted Radiotherapy Candidate FAP-2286 at SNMMI Annual Meeting

Pharmaceutical startup CLVS stock is climbing 25% higher today on rumors that the cancer drug maker has become a takeover target. The post Clovis Oncology (CLVS) Stock Rallies on Buyout Rumors appeared first on InvestorPlace.

Clovis Oncology (CLVS) Stock Rallies on Buyout Rumors

Kaival Brands Innovations Group

Here's what you need to know about trading penny stocks on June 14th The post What to Know About Trading Penny Stocks on June 14th  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

What to Know About Trading Penny Stocks on June 14th

Amarin Corporation Plc

Quoin Pharmaceuticals Ltd

Penny stocks to watch The post Penny Stocks To Buy Now? 4 To Watch With Big News appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Penny Stocks To Buy Now? 4 To Watch With Big News

BOULDER, Colo.--(BUSINESS WIRE)---- $CLVS--Clovis Oncology's Rubraca® (Rucaparib) as First-Line Maintenance Treatment Significantly Improves Progression-Free Survival in Women ...

Clovis Oncology's Rubraca® (Rucaparib) as First-Line Maintenance Treatment Significantly Improves Progression-Free Survival in Women with Advanced Ovarian Cancer in Primary Efficacy Analyses Regardless of BRCA Mutation and HRD Status

Clovis (CLVS) reported earnings 30 days ago. What's next for the stock?

Why Is Clovis (CLVS) Down 55.2% Since Last Earnings Report?

Axsome Therapeutics

These gems are hiding in a sector that has been pummeled so far this year.

2 Biotech Stocks That Could Go Parabolic

Investors bailed from the company after a quarterly results and operational update.

Why Clovis Oncology Stock Was Plummeting This Week

BOULDER, Colo.--(BUSINESS WIRE)---- $CLVS--Clovis Oncology to Present at the BofA Securities 2022 Healthcare Conference

Clovis Oncology to Present at the BofA Securities 2022 Healthcare Conference

Clovis (CLVS) incurs wider-than-estimated loss for first-quarter 2022. Sales of the sole marketed drug Rubraca decline year over year due to COVID-19 impacts.

Clovis (CLVS) Q1 Loss Wider than Expected, Revenues Miss

Clovis Oncology, Inc. (NASDAQ:CLVS ) Q1 2022 Earnings Conference Call May 4, 2022 8:30 AM ET Company Participants Anna Sussman - VP, IR and Corporate Communications Patrick Mahaffy - President and CEO Thomas Harding - Chief Scientific Officer Dan Muehl - CFO Conference Call Participants Charlie Ferranti - Goldman Sachs Operator Good morning. And welcome to the Clovis Oncology First Quarter 2022 Operating Results Conference Call.

News for Clovis Oncology Stock (CLVS)